Back to Journals » Lung Cancer: Targets and Therapy » Volume 14
![](https://www.dovepress.com/cr_data/cache/journal_image/83/cope/thumb_100_1000_100.jpg)
Lung Cancer: Targets and Therapy
ISSN: 1179-2728
- View all (183)
- Volume 15, 2024 (11)
- Volume 14, 2023 (12)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Archive: Volume 14, 2023
Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
Nagasaka M, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:101-109
Published Date: 12 December 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer
![](cr_data/cache/article_graphical_abstract/s430967/graphical_abstract.jpg)
Shi J, Li J, Wang H, Li X, Wang Q, Zhao C, Cheng L, Han R, Chen P, Guo H, Tang Z, Zhou C, Zhang Z, Wu F
Lung Cancer: Targets and Therapy 2023, 14:85-99
Published Date: 21 November 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
Wang L, Quan F, Guo Z, Lu Z, Yang D, Shi M
Lung Cancer: Targets and Therapy 2023, 14:79-84
Published Date: 9 October 2023
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:71-78
Published Date: 7 July 2023
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Brazel D, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:63-69
Published Date: 23 June 2023
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:57-62
Published Date: 22 June 2023
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer
Deck J, Hartley M, Akhter M, Wang D, Bogart JA, Mix MD
Lung Cancer: Targets and Therapy 2023, 14:47-55
Published Date: 19 May 2023
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
Lee ATM, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:41-46
Published Date: 25 April 2023
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel D, Kim J, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:31-39
Published Date: 20 April 2023
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
Zhang SS, Lee A, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:27-30
Published Date: 19 April 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
Nigro MC, Marchese PV, Deiana C, Casadio C, Galvani L, Di Federico A, De Giglio A
Lung Cancer: Targets and Therapy 2023, 14:11-25
Published Date: 3 February 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
Brazel D, Ou SI, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:1-9
Published Date: 5 January 2023